Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-10-2011 | Preclinical study

Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs

Authors: A. Smeets, A. Daemen, I. Vanden Bempt, O. Gevaert, B. Claes, H. Wildiers, R. Drijkoningen, P. Van Hummelen, D. Lambrechts, B. De Moor, P. Neven, C. Sotiriou, T. Vandorpe, R. Paridaens, M. R. Christiaens

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Abstract

The aim of this study was to investigate whether lymph node involvement in breast cancer is influenced by gene or miRNA expression of the primary tumor. For this purpose, we selected a very homogeneous patient population to minimize heterogeneity in other tumor and patient characteristics. First, we compared gene expression profiles of primary tumor tissue from a group of 96 breast cancer patients balanced for lymph node involvement using Affymetrix Human U133 Plus 2.0 microarray chip. A model was built by weighted Least-Squares Support Vector Machines and validated on an internal and external dataset. Next, miRNA profiling was performed on a subset of 82 tumors using Human MiRNA-microarray chips (Illumina). Finally, for each miRNA the number of significant inverse correlated targets was determined and compared with 1000 sets of randomly chosen targets. A model based on 241 genes was built (AUC 0.66). The AUC for the internal dataset was 0.646 and 0. 651 for the external datasets. The model includes multiple kinases, apoptosis-related, and zinc ion-binding genes. Integration of the microarray and miRNA data reveals ten miRNAs suppressing lymph node invasion and one miRNA promoting lymph node invasion. Our results provide evidence that measurable differences in gene and miRNA expression exist between node negative and node positive patients and thus that lymph node involvement is not a genetically random process. Moreover, our data suggest a general deregulation of the miRNA machinery that is potentially responsible for lymph node invasion.
Appendix
Available only for authorised users
Literature
1.
Shek LL, Godolphin W (1988) Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48:5565–5569PubMed
2.
Weigelt B, Peterse JL, van‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602PubMedCrossRef
3.
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK (1999) Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17(8):2334–2340PubMed
4.
Mittra I, MacRae KD (1991) A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology of chronology? Eur J Cancer 27(12):1574–1583PubMedCrossRef
5.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8):567–575PubMedCrossRef
6.
Koscielny S, Le MG, Tubiana M (1989) The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 59:775–782PubMedCrossRef
7.
Yip CH, Taib NA, Tan GH, Ng KL, Yoong BK, Choo WY (2009) Predictors of axillary lymph node metastases in breast cancer: is there a role for minimal axillary surgery? Word J Surg 33:54–57CrossRef
8.
Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP (2000) Predictive factors associated with axillary lymph node metastases in T1a en T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 191(1):1–6PubMedCrossRef
9.
Wildiers H, Van Calster B, van de Poll-Franse LV et al (2009) Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 27(18):2931–2937PubMedCrossRef
10.
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef
11.
Huang E, Cheng SH, Dressman H et al (2003) Gene expression predictors of breast cancer outcomes. Lancet 361(9369):1590–1596PubMedCrossRef
12.
Weigelt B, Wessels LFA, Bosma AJ et al (2005) No common denominator for breast cancer lymph node metastasis. Br J Cancer 93(8):924–932PubMedCrossRef
13.
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531PubMedCrossRef
14.
Ng EK, Wong CLP, Ma ES, Kwong A (2009) MircroRNAs as new players for diagnosis, prognosis and therapeutic targets in breast cancer. J Oncol 2009:305420PubMed
15.
Heneghan HM, Miller N, Kerin MJ (2010) MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 10:1–8CrossRef
16.
Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, Torrela-Ramos A, Salvador-Sanchis JL (2009) Disease-free survival and prognostic significance of metastatic lymph node ratio in T1–T2 N positive breast cancer patients. A population registry-based study in a European country. World J Surg 33:1659–1664PubMedCrossRef
17.
Suykens JAK, Van Gestel T, De Brabanter J, De Moor B, Vandewalle J (2002) Least squares support vector machines. World Scientific, SingaporeCrossRef
18.
Suykens JAK, Vandewalle J (1999) Least squares support vector machine classifiers. Neural Process Lett 9:293–300CrossRef
19.
Cawley GC (2006) Leave-one-out cross-validation based model selection criteria for weighted LS-SVMs. Proc Int Joint Conf Neural Netw 1661–1668
20.
Berezikov E, vanTetering G, Verheul M et al (2006) Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. Genome Res 16:1289–1298PubMedCrossRef
21.
Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36:D149–D153PubMedCrossRef
22.
Zhang B, Schmoyer D, Kirov S, Snoddy J (2004) GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 5:16PubMedCrossRef
23.
Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545–15550PubMedCrossRef
24.
Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18(1):27–34PubMedCrossRef
25.
van Kempen LCLT, Ruiter DJ, van Muijen GNP, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82(11):539–558PubMedCrossRef
26.
Bogenrieder T, Herlyn M (2003) Axils of evil: molecular mechanisms of cancer metastasis. Oncogene 22(42):6524–6536PubMedCrossRef
27.
Sheu BC, Kuo WH, Chen RJ, Huang SC, Chang KJ, Chow SN (2008) Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 17(6):604–610PubMedCrossRef
28.
Macchetti AH, Marana HRC, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S (2006) Tumor-infiltrating CD4+T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 61(3):203–208PubMedCrossRef
29.
Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23(29):7332–7341PubMedCrossRef
30.
Michiels S, Koscielny S, Hill C (2007) Interpretion of microarray data in cancer. Br J Cancer 96(8):1155–1158PubMedCrossRef
31.
Ding WQ, Yu HJ, Lind SE (2008) Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett 271(2):251–259PubMedCrossRef
32.
Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S (2005) The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 25(18):7953–7965PubMedCrossRef
33.
Apte RN, Dotan S, Elkabets M et al (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387–408PubMedCrossRef
34.
Zhang C, Chakravarty D, Sakabe I et al (2006) Role of SCC-S2 in experitmental metastasis and modulation of VEGFR-2, MMP-1, an d MMP-9 expression. Mol Ther 13(5):947–955PubMedCrossRef
35.
Németh J, Stein H, Haag D et al (2009) S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 50(4):1251–1262PubMedCrossRef
36.
Kanda M, Nomoto S, Nishikawa Y et al (2008) Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 98(3):190–196PubMedCrossRef
37.
Fan F, Wey JS, McCarty MF et al (2005) Expression and foundation of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24(16):2647–2653PubMedCrossRef
38.
Wey JS, Fan F, Gray MJ et al (2005) Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104(2):427–438PubMedCrossRef
39.
Gunningham SP, Currie MJ, Han C et al (2001) VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol 193(3):325–332PubMedCrossRef
40.
Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375PubMedCrossRef
41.
Van’t Veer L, Dai H, van de Vijver M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536CrossRef
42.
Hao X, Sun B, Hu L et al (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100(6):1110–1122PubMedCrossRef
43.
Nishidate T, Katagiri T, Lin ML et al (2004) Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25(4):797–819PubMed
44.
Li X, Cao X, Li X, Zhang W, Feng Y (2007) Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 98(10):1592–1596PubMedCrossRef
45.
Abdelmohsen K, Kim MM, Srikantan S, et al. (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9(7):1538–4101
46.
Yang N, Kaur S, Volinia S et al (2008) MicroRNA microarray indentifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307–10314PubMedCrossRef
47.
Bhattacharya R, Nicoloso M, Arvizo R et al (2009) MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 69(23):9090–9095PubMedCrossRef
48.
Tsukamoto Y, Nakada C, Noguchi T et al (2010) Micro-RNA-375 Is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14–3-3. Cancer Res 70(6):2339–2349PubMedCrossRef
49.
Arndt GM, Dossey L, Cullen LM et al (2009) Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9:374PubMedCrossRef
50.
Villanueva A, Hoshida Y, Toffanin S et al (2010) New strategies in Hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16(19):4688–4994PubMedCrossRef
Metadata
Title
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs
Authors
A. Smeets
A. Daemen
I. Vanden Bempt
O. Gevaert
B. Claes
H. Wildiers
R. Drijkoningen
P. Van Hummelen
D. Lambrechts
B. De Moor
P. Neven
C. Sotiriou
T. Vandorpe
R. Paridaens
M. R. Christiaens
Publication date
01-10-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1265-5

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Epidemiology

Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population

Letter to the Editor

Regarding the article “The p160 ER co-regulators predict outcome in ER negative breast cancer” by Spears, Oesterreich, Migliaccio et al. published in Breast Cancer Res Treat, March 2011

Preclinical study

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer

Letter to the Editor

RAD51C germline mutations in Chinese women with familial breast cancer

Clinical Trial

Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation

Preclinical study

Multicentric breast cancer: clonality and prognostic studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits